These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 12234304)

  • 21. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature.
    Emerson M; Momi S; Paul W; Alberti PF; Page C; Gresele P
    Thromb Haemost; 1999 Jun; 81(6):961-6. PubMed ID: 10404776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble CD40 Ligand and Oxidative Response Are Reciprocally Stimulated during Shiga Toxin-Associated Hemolytic Uremic Syndrome.
    Abrey Recalde MJ; Alvarez RS; Alberto F; Mejias MP; Ramos MV; Fernandez Brando RJ; Bruballa AC; Exeni RA; Alconcher L; Ibarra CA; Amaral MM; Palermo MS
    Toxins (Basel); 2017 Oct; 9(11):. PubMed ID: 29068360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes.
    Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA
    Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recovery of thalamic microstructural damage after Shiga toxin 2-associated hemolytic-uremic syndrome.
    Krämer J; Deppe M; Göbel K; Tabelow K; Wiendl H; Meuth SG
    J Neurol Sci; 2015 Sep; 356(1-2):175-83. PubMed ID: 26189050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ingested Shiga toxin 2 (Stx2) causes histopathological changes in kidney, spleen, and thymus tissues and mortality in mice.
    Rasooly R; Do PM; Griffey SM; Vilches-Moure JG; Friedman M
    J Agric Food Chem; 2010 Aug; 58(16):9281-6. PubMed ID: 20681531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracerebroventricular administration of Shiga toxin type 2 altered the expression levels of neuronal nitric oxide synthase and glial fibrillary acidic protein in rat brains.
    Boccoli J; Loidl CF; Lopez-Costa JJ; Creydt VP; Ibarra C; Goldstein J
    Brain Res; 2008 Sep; 1230():320-33. PubMed ID: 18675791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression profile and injury sites in mice treated with Shiga toxin 2 and lipopolysaccharide as a Shiga toxin-associated hemolytic uremic syndrome model.
    Kume Y; Go H; Maeda R; Suyama K; Mori T; Kawasaki Y; Hashimoto K; Hosoya M
    Physiol Genomics; 2022 May; 54(5):153-165. PubMed ID: 35384732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of shiga toxin 2.
    Silberstein C; Lucero MS; Zotta E; Copeland DP; Lingyun L; Repetto HA; Ibarra C
    Pediatr Res; 2011 May; 69(5 Pt 1):390-4. PubMed ID: 21270676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemokine receptor CCR1 disruption limits renal damage in a murine model of hemolytic uremic syndrome.
    Ramos MV; Auvynet C; Poupel L; Rodero M; Mejias MP; Panek CA; Vanzulli S; Combadiere C; Palermo M
    Am J Pathol; 2012 Mar; 180(3):1040-1048. PubMed ID: 22203055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. von Willebrand Factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome.
    Pysher TJ; Siegler RL; Tesh VL; Taylor FB
    Pediatr Dev Pathol; 2002; 5(5):472-9. PubMed ID: 12196894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic use of selective iNOS inhibitor 1400W or non-selective NOS inhibitor l-NAME differently affects systemic nitric oxide formation after oral Porphyromonas gingivalis inoculation in mice.
    Nemec A; Pavlica Z; Petelin M; Crossley DA; Sentjurc M; Jerin A; Erzen D; Zdovc I; Hitti T; Skaleric U
    Arch Oral Biol; 2010 Jul; 55(7):509-14. PubMed ID: 20430367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome.
    Tazzari PL; Ricci F; Carnicelli D; Caprioli A; Tozzi AE; Rizzoni G; Conte R; Brigotti M
    Cytometry B Clin Cytom; 2004 Sep; 61(1):40-4. PubMed ID: 15351981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of an experimental hemolytic uremic syndrome in rats.
    Zotta E; Lago N; Ochoa F; Repetto HA; Ibarra C
    Pediatr Nephrol; 2008 Apr; 23(4):559-67. PubMed ID: 18253762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microparticle generation and leucocyte death in Shiga toxin-mediated HUS.
    Ge S; Hertel B; Emden SH; Beneke J; Menne J; Haller H; von Vietinghoff S
    Nephrol Dial Transplant; 2012 Jul; 27(7):2768-75. PubMed ID: 22234918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nitric oxide/platelet activating factor cross-talk in mesangial cells modulates the interaction with leukocytes.
    Bussolati B; Mariano F; Migliori M; Camussi G
    Kidney Int; 2002 Oct; 62(4):1322-31. PubMed ID: 12234302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
    Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
    Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.
    Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M
    J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of complement in enterohemorrhagic Escherichia coli-Induced hemolytic uremic syndrome.
    Orth-Höller D; Würzner R
    Semin Thromb Hemost; 2014 Jun; 40(4):503-7. PubMed ID: 24799304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of cholinergic airway reactivity and nitric oxide production by endogenous arginase activity.
    Meurs H; Hamer MA; Pethe S; Vadon-Le Goff S; Boucher JL; Zaagsma J
    Br J Pharmacol; 2000 Aug; 130(8):1793-8. PubMed ID: 10952667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell-type specific interaction of endothelin and the nitric oxide system: pattern of prepro-ET-1 expression in kidneys of L-NAME treated prepro-ET-1 promoter-lacZ-transgenic mice.
    Slowinski T; Kalk P; Christian M; Schmager F; Relle K; Godes M; Funke-Kaiser H; Neumayer HH; Bauer C; Theuring F; Hocher B
    J Physiol; 2007 Jun; 581(Pt 3):1173-81. PubMed ID: 17395629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.